thalidomide has been researched along with Cancer of Prostate in 75 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These included Grade 3 neutropenia precluding planned paclitaxel therapy (n = 3), grade 3 gastrointestinal toxicity (n = 2), chest pain (n = 1) and pulmonary embolism (n = 1)." | 5.14 | A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. ( Bekele, NB; Carter, CM; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM, 2010) |
| "Treatment with lenalidomide was associated with global changes in immunoreactivity to a number of prostate-associated antigens, as well as with changes in circulating levels of the T(H) 2 cytokines IL-4, IL-5, IL-10, and IL-13." | 2.77 | Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. ( Antonarakis, ES; Carducci, M; Drake, CG; Eisenberger, MA; Keizman, D; McNeel, DG; Smith, HA; Thoburn, CJ; Zabransky, DJ; Zahurak, M, 2012) |
| "Thalidomide is an active anticancer agent and also shows wide pharmacological variation." | 2.75 | A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. ( Cormier, T; Dahut, WL; Deeken, JF; Figg, WD; Liewehr, DJ; Miao, X; Price, DK; Sissung, TM; Steinberg, SM; Tran, K, 2010) |
| "Lenalidomide has acceptable toxicity and is associated with long-term disease stabilization and PSA declines." | 2.75 | Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. ( Antonarakis, ES; Carducci, M; Denmeade, S; Drake, C; Eisenberger, M; Hudock, S; Keizman, D; Pili, R; Sinibaldi, V; Zahurak, M, 2010) |
| "Thalidomide was tolerable although dose reductions occurred in 47% (58 of 124) of patients." | 2.74 | A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. ( Aragon-Ching, JB; Arlen, PM; Chatta, GS; Dahut, WL; Figg, WD; Gulley, JL; Higano, CS; Hussain, MH; Parnes, H; Petrylak, DP; Sartor, O; Steinberg, SM; Wright, JJ, 2009) |
| "Thalidomide was well tolerated and induced a median reduction in prostate-specific antigen of 41% without affecting testosterone." | 2.73 | Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. ( Do, KA; Efstathiou, E; Logothetis, CJ; McDonnell, TJ; Pettaway, CA; Pisters, LL; Troncoso, P; Wen, S, 2007) |
| "Thalidomide was started on day 1 at the assigned dose and continued for four consecutive weeks; oral cyclophosphamide (50 mg for day) was given for four consecutive weeks (1 cycle) starting on the same day initiating thalidomide." | 2.73 | Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. ( Autorino, R; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Forestieri, V; Giugliano, F; Imbimbo, C; Mirone, V; Prudente, A; Romano, C, 2007) |
| "Locally advanced prostate cancer patients undergoing radical prostatectomy were recruited for this study." | 2.73 | Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. ( Dreicer, R; Elson, P; Garcia, JA; Klein, EA; Magi-Galluzzi, C; Triozzi, P, 2008) |
| "The combined dosing of paclitaxel (100 mg/m(2) weekly), doxorubicin (20 mg/m(2) weekly), and thalidomide (300 mg daily) is tolerated by men with AIPC and merits continued phase II study." | 2.72 | A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer. ( Amato, RJ; Sarao, H, 2006) |
| "Thalidomide was discontinued in 55 patients for lack of therapeutic response." | 2.70 | Thalidomide neuropathy in patients treated for metastatic prostate cancer. ( Culcea, E; Dahut, W; Figg, WD; Floeter, MK; Kruger, EA; Molloy, FM; Pluda, J; Reed, E; Sandbrink, F; Steinberg, SM; Syed, NA, 2001) |
| "Prostate cancer is dependent on the recruitment of new blood vessels to grow and metastasize." | 2.70 | A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. ( Chen, CC; Dahut, W; Dixon, S; Duray, P; Figg, WD; Floeter, MK; Gubish, E; Hamilton, M; Jones, E; Kohler, DR; Krüger, EA; Linehan, WM; Pluda, JM; Premkumar, A; Reed, E; Steinberg, SM; Tompkins, A, 2001) |
| "Thalidomide has been shown to inhibit the ability of tumors to recruit new blood vessels." | 2.70 | A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. ( Arlen, P; Dahut, WL; Fedenko, K; Fernandez, P; Figg, WD; Gulley, J; Hamilton, M; Kruger, EA; Noone, M; Parker, C; Pluda, J, 2001) |
| " Serial serum or blood samples were obtained for pharmacokinetic assessment after administration of a single oral dose or multiple daily dosing of thalidomide and were assayed by reversed-phase HPLC." | 2.69 | Pharmacokinetics of thalidomide in an elderly prostate cancer population. ( Bauer, KS; Bergan, R; Chen, A; Figg, WD; Hamilton, M; Pluda, J; Raje, S; Reed, E; Tompkins, A; Venzon, D, 1999) |
| "Despite multiple advances in prostate cancer therapy, treatment options for castration resistant disease are very limited." | 2.47 | Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. ( Espinosa, E; González, R; Merino, M; Pinto, A, 2011) |
| "Once, prostate cancer becomes hormone-refractory, there are only a few effective therapies such as docetaxel-based chemotherapies." | 2.44 | [Molecular-targeted therapy for prostate cancer]. ( Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H, 2008) |
| "Hormone-refractory prostate cancer (HRPC) remains true to its name: it is largely refractory to attempts to delay its progression." | 2.43 | Future therapies in hormone-refractory prostate cancer. ( Nelson, JB; Smith, MR, 2005) |
| "Hormone refractory prostate cancer (HRPC) remains a challenge in the management of prostate cancer patients." | 2.42 | Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges. ( Carducci, MA; Rosenbaum, E, 2003) |
| "It is now well established that cancer growth is increased by angiogenic factors and that inhibition of angiogenesis decreases growth and metastatic potential." | 2.42 | [Anti angiogenesis]. ( Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N, 2004) |
| "Thalidomide has long been recognized as an antiangiogenic molecule." | 2.42 | Thalidomide and analogues: current proposed mechanisms and therapeutic usage. ( Brennen, WN; Brown, ML; Capitosti, S; Cooper, CR; Sikes, RA, 2004) |
| "Thalidomide has been shown to block the activity of angiogenic substances like bFGF, VEGF and interleukin 6." | 2.41 | [Thalidomide. Clinical trials in cancer]. ( Politi, PM, 2000) |
| "Thalidomide was used in the late 1950s and early 1960s as a sedative for morning sickness in pregnant women." | 1.48 | Robotic assisted radical prostatectomy for localised prostate cancer in thalidomide generation. ( Ashton, A; Kusuma, VRM; Moschanos, D; Patil, K; Perry, M, 2018) |
| "Aim of study - prostate cancer is second most common cancer in men worldwide, and fifth leading cause of death from cancer in men (6." | 1.46 | MODULATION OF ANTITUMOR IMMUNE RESPONSE IN MOUSE PROSTATE CANCER MODEL. ( Guruli, G; Matchavariani, K; Mchedlishvili, K; Mitskevich, N; Tsertsvadze, T, 2017) |
| "Decreased expression of CTA by prostate cancer may be a means of escaping immune monitoring." | 1.46 | Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model. ( Goliadze, E; Guruli, G; Manjili, MH; Petrossian, AA; Robinson, SP; Sulek, JE; Toor, A; Zhou, S, 2017) |
| "Immunotherapy is moving forward in prostate cancer." | 1.43 | ( Angelergues, A; Mejean, A; Michel, C; Oudard, S; Tartour, E; Thibault, C; Timsit, MO; Vano, Y, 2016) |
| "Treatment of castration-resistant prostate cancer (CRPC) remains a challenge considering that most patients are elderly men with significant comorbidities." | 1.38 | Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib. ( Marschner, N; Zaiss, M, 2012) |
| "Patients with androgen-independent prostate cancer treated with docetaxel alone (n = 23) or docetaxel and thalidomide (n = 50) were genotyped for the ABCB1 1236C>T, 2677 G>T/A, and 3435 C>T alleles by direct sequencing, and diplotypes were constructed using an EM algorithm." | 1.35 | ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. ( Aragon-Ching, J; Baum, CE; Dahut, W; Deeken, J; Figg, WD; Price, DK; Sissung, TM; Sparreboom, A; Steinberg, SM, 2008) |
| "A report into recurrent prostate cancer by Figg et al." | 1.35 | Prostate cancer: thalidomide for prostate cancer: is there progress? ( Efstathiou, E; Logothetis, CJ, 2009) |
| "A human prostate cancer xenograft model was used to evaluate the effect of either thalidomide, docetaxel or a combination of the two drugs on circulating ECs." | 1.35 | Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. ( Bertolini, F; Figg, WD; Li, H; Price, DK; Raia, V, 2008) |
| "Thalidomide was found to demonstrate selective inhibition of androgen receptor positive LNCaP prostate cancer cells." | 1.32 | Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer. ( Brown, ML; Capitosti, SM; Hansen, TP, 2004) |
| "Thalidomide has demonstrated clinical activity in various malignancies including androgen-independent prostate cancer." | 1.32 | Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. ( Eger, K; Figg, WD; Gütschow, M; MacPherson, GR; Ng, SS, 2004) |
| "In patients with metastatic prostate cancer, we are evaluating the addition of the bisphosphonate alendronate when added to ketoconazole for impact on matrix metalloproteinase (MMP)-2 and MMP-9 as well as traditional clinical endpoints." | 1.31 | National Cancer Institute intramural approach to advanced prostate cancer. ( Arlen, PM; Cox, MC; Dahut, W; Figg, WD; Gulley, J; Linehan, WM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (5.33) | 18.2507 |
| 2000's | 47 (62.67) | 29.6817 |
| 2010's | 23 (30.67) | 24.3611 |
| 2020's | 1 (1.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hawley, JE | 1 |
| Pan, S | 1 |
| Figg, WD | 24 |
| Lopez-Bujanda, ZA | 1 |
| Strope, JD | 1 |
| Aggen, DH | 1 |
| Dallos, MC | 1 |
| Lim, EA | 1 |
| Stein, MN | 1 |
| Hu, J | 1 |
| Drake, CG | 2 |
| Mitskevich, N | 1 |
| Tsertsvadze, T | 1 |
| Mchedlishvili, K | 1 |
| Matchavariani, K | 1 |
| Guruli, G | 2 |
| Dai, X | 1 |
| Gan, W | 1 |
| Li, X | 1 |
| Wang, S | 1 |
| Zhang, W | 1 |
| Huang, L | 1 |
| Liu, S | 1 |
| Zhong, Q | 1 |
| Guo, J | 1 |
| Zhang, J | 1 |
| Chen, T | 1 |
| Shimizu, K | 1 |
| Beca, F | 1 |
| Blattner, M | 1 |
| Vasudevan, D | 1 |
| Buckley, DL | 1 |
| Qi, J | 1 |
| Buser, L | 1 |
| Liu, P | 1 |
| Inuzuka, H | 1 |
| Beck, AH | 1 |
| Wang, L | 1 |
| Wild, PJ | 1 |
| Garraway, LA | 1 |
| Rubin, MA | 1 |
| Barbieri, CE | 1 |
| Wong, KK | 1 |
| Muthuswamy, SK | 1 |
| Huang, J | 1 |
| Chen, Y | 1 |
| Bradner, JE | 1 |
| Wei, W | 1 |
| Kusuma, VRM | 1 |
| Ashton, A | 1 |
| Moschanos, D | 1 |
| Patil, K | 1 |
| Perry, M | 1 |
| Sundaresan, L | 1 |
| Kumar, P | 1 |
| Chatterjee, S | 1 |
| Chen, L | 1 |
| Qiu, X | 1 |
| Wang, R | 1 |
| Xie, X | 1 |
| Zalazar, F | 1 |
| De Luca, P | 1 |
| Gardner, K | 1 |
| Meiss, R | 1 |
| Spallanzani, RG | 1 |
| Vallecorsa, P | 1 |
| Elguero, B | 1 |
| Cotignola, J | 1 |
| Vazquez, E | 1 |
| De Siervi, A | 1 |
| Sulek, JE | 1 |
| Robinson, SP | 1 |
| Petrossian, AA | 1 |
| Zhou, S | 1 |
| Goliadze, E | 1 |
| Manjili, MH | 1 |
| Toor, A | 1 |
| Oudard, S | 1 |
| Thibault, C | 1 |
| Angelergues, A | 1 |
| Tartour, E | 1 |
| Timsit, MO | 1 |
| Mejean, A | 1 |
| Michel, C | 1 |
| Vano, Y | 1 |
| Sissung, TM | 3 |
| Baum, CE | 1 |
| Deeken, J | 1 |
| Price, DK | 4 |
| Aragon-Ching, J | 1 |
| Steinberg, SM | 9 |
| Dahut, W | 6 |
| Sparreboom, A | 1 |
| Gulley, JL | 6 |
| Aragon-Ching, JB | 3 |
| Hussain, MH | 2 |
| Sartor, O | 3 |
| Higano, CS | 2 |
| Petrylak, DP | 3 |
| Chatta, GS | 2 |
| Arlen, PM | 6 |
| Dahut, WL | 10 |
| Parnes, H | 4 |
| Wright, JJ | 5 |
| Efstathiou, E | 2 |
| Logothetis, CJ | 3 |
| Ning, YM | 2 |
| Patten, DY | 1 |
| Thordardottir, S | 1 |
| Gardner, ER | 1 |
| Deeken, JF | 1 |
| Cormier, T | 1 |
| Tran, K | 1 |
| Liewehr, DJ | 1 |
| Miao, X | 1 |
| Mathew, P | 2 |
| Tannir, N | 1 |
| Tu, SM | 1 |
| Carter, CM | 1 |
| Bekele, NB | 1 |
| Pagliaro, L | 1 |
| Woo, S | 1 |
| Parnes, HL | 1 |
| Trepel, JB | 1 |
| Lee, MJ | 1 |
| Kim, YS | 1 |
| Sun, H | 1 |
| Madan, RA | 1 |
| Latham, L | 2 |
| Jones, E | 4 |
| Chen, CC | 3 |
| Keizman, D | 2 |
| Zahurak, M | 2 |
| Sinibaldi, V | 1 |
| Carducci, M | 2 |
| Denmeade, S | 1 |
| Drake, C | 1 |
| Pili, R | 1 |
| Antonarakis, ES | 2 |
| Hudock, S | 1 |
| Eisenberger, M | 1 |
| Rexer, H | 1 |
| Merino, M | 1 |
| Pinto, A | 1 |
| González, R | 1 |
| Espinosa, E | 1 |
| Otto, S | 1 |
| Schreyer, C | 1 |
| Hafner, S | 1 |
| Mast, G | 1 |
| Ehrenfeld, M | 1 |
| Stürzenbaum, S | 1 |
| Pautke, C | 1 |
| Zabransky, DJ | 1 |
| Smith, HA | 1 |
| Thoburn, CJ | 1 |
| Eisenberger, MA | 1 |
| McNeel, DG | 1 |
| Henry, JY | 1 |
| Lu, L | 1 |
| Adams, M | 1 |
| Meyer, B | 1 |
| Bartlett, JB | 1 |
| Dalgleish, AG | 2 |
| Galustian, C | 1 |
| Meng, LJ | 1 |
| Wang, J | 1 |
| Fan, WF | 1 |
| Pu, XL | 1 |
| Liu, FY | 1 |
| Yang, M | 1 |
| Ren, S | 1 |
| Xu, C | 1 |
| Cui, Z | 1 |
| Yu, Y | 1 |
| Xu, W | 1 |
| Wang, F | 1 |
| Lu, J | 1 |
| Wei, M | 1 |
| Lu, X | 1 |
| Gao, X | 1 |
| Liang, Y | 1 |
| Mao, JH | 1 |
| Sun, Y | 1 |
| Nabhan, C | 1 |
| Marschner, N | 1 |
| Zaiss, M | 1 |
| Lin, J | 1 |
| Kelly, WK | 1 |
| Rezvani, H | 1 |
| Haghighi, S | 1 |
| Ghadyani, M | 1 |
| Attarian, H | 1 |
| Leibowitz, R | 1 |
| Tucker, SJ | 1 |
| Mohla, S | 1 |
| Weilbacher, KN | 1 |
| Cher, ML | 1 |
| Oyajobi, BO | 1 |
| Poznak, CV | 1 |
| Clohisy, DR | 1 |
| Marriott, JB | 1 |
| Clarke, IA | 1 |
| Czajka, A | 1 |
| Dredge, K | 1 |
| Childs, K | 1 |
| Man, HW | 1 |
| Schafer, P | 1 |
| Govinda, S | 1 |
| Muller, GW | 1 |
| Stirling, DI | 1 |
| Horne, MK | 1 |
| Arlen, P | 3 |
| Gulley, J | 4 |
| Parker, C | 3 |
| Lakhani, N | 1 |
| Drake, MJ | 1 |
| Robson, W | 1 |
| Mehta, P | 1 |
| Schofield, I | 1 |
| Neal, DE | 1 |
| Leung, HY | 1 |
| Rosenbaum, E | 1 |
| Carducci, MA | 1 |
| Ng, SS | 3 |
| Gütschow, M | 2 |
| Weiss, M | 1 |
| Hauschildt, S | 1 |
| Teubert, U | 1 |
| Hecker, TK | 1 |
| Luzzio, FA | 1 |
| Kruger, EA | 4 |
| Eger, K | 2 |
| Macpherson, GR | 2 |
| Franks, M | 1 |
| Tomoaia-Cotisel, A | 1 |
| Ando, Y | 1 |
| Capitosti, SM | 1 |
| Hansen, TP | 1 |
| Brown, ML | 2 |
| Grover, JK | 1 |
| Vats, K | 1 |
| Tyagi, P | 1 |
| Price, N | 1 |
| Reddy, K | 1 |
| Klem, J | 1 |
| Cox, MC | 1 |
| Linehan, WM | 3 |
| Tohnya, TM | 1 |
| Zeldis, J | 1 |
| Akaza, H | 1 |
| Nakagawa, M | 1 |
| Tsuruo, T | 1 |
| Saijo, N | 1 |
| Sone, S | 1 |
| Yamamoto, N | 1 |
| Kakeji, Y | 1 |
| Nakamura, S | 1 |
| Kurebayashi, J | 1 |
| Isonishi, S | 1 |
| Ohashi, Y | 1 |
| Blackledge, G | 1 |
| Carmichael, J | 1 |
| Cohen, MR | 1 |
| Liu, Y | 1 |
| Fedenko, KM | 1 |
| Parker, CE | 1 |
| Brennen, WN | 1 |
| Cooper, CR | 1 |
| Capitosti, S | 1 |
| Sikes, RA | 1 |
| Ozkan, M | 1 |
| Eser, B | 1 |
| Er, O | 1 |
| Dogu, GG | 1 |
| Altinbas, M | 1 |
| Smith, MR | 1 |
| Nelson, JB | 1 |
| Zhao, D | 1 |
| Jiang, L | 1 |
| Hahn, EW | 1 |
| Mason, RP | 1 |
| Amato, RJ | 1 |
| Sarao, H | 1 |
| Nishimura, K | 2 |
| Takayama, H | 2 |
| Nakayama, M | 2 |
| Nonomura, N | 2 |
| Okuyama, A | 2 |
| Dieringer, PY | 1 |
| Chen, I | 1 |
| Pagliaro, LC | 1 |
| Bekele, BN | 1 |
| Zhou, X | 1 |
| Daliani, DD | 1 |
| Troncoso, P | 1 |
| Wen, S | 1 |
| Do, KA | 1 |
| Pettaway, CA | 1 |
| Pisters, LL | 1 |
| McDonnell, TJ | 1 |
| Di Lorenzo, G | 1 |
| Autorino, R | 1 |
| De Laurentiis, M | 1 |
| Forestieri, V | 1 |
| Romano, C | 1 |
| Prudente, A | 1 |
| Giugliano, F | 1 |
| Imbimbo, C | 1 |
| Mirone, V | 1 |
| De Placido, S | 1 |
| Li, H | 2 |
| Sissung, T | 1 |
| Retter, A | 1 |
| Wu, S | 1 |
| Fedenko, K | 2 |
| Chen, C | 1 |
| Al-Chalabi, T | 1 |
| Raia, V | 1 |
| Bertolini, F | 1 |
| Zhu, D | 1 |
| Corral, LG | 1 |
| Fleming, YW | 1 |
| Stein, B | 1 |
| Garcia, JA | 1 |
| Klein, EA | 1 |
| Magi-Galluzzi, C | 1 |
| Elson, P | 1 |
| Triozzi, P | 1 |
| Dreicer, R | 1 |
| Pollard, M | 1 |
| Joseph, IB | 1 |
| Isaacs, JT | 1 |
| Raje, S | 1 |
| Bauer, KS | 1 |
| Tompkins, A | 2 |
| Venzon, D | 1 |
| Bergan, R | 1 |
| Chen, A | 1 |
| Hamilton, M | 3 |
| Pluda, J | 3 |
| Reed, E | 3 |
| Guinan, P | 1 |
| Shaw, M | 1 |
| Mirochnik, Y | 1 |
| Slobodskoy, L | 1 |
| Ray, V | 1 |
| Rubenstein, M | 1 |
| Politi, PM | 1 |
| Molloy, FM | 1 |
| Floeter, MK | 2 |
| Syed, NA | 1 |
| Sandbrink, F | 1 |
| Culcea, E | 1 |
| Duray, P | 1 |
| Premkumar, A | 1 |
| Dixon, S | 1 |
| Kohler, DR | 1 |
| Gubish, E | 1 |
| Pluda, JM | 1 |
| Fernandez, P | 1 |
| Noone, M | 1 |
| Morris, MJ | 1 |
| Scher, HI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation[NCT00004635] | Phase 3 | 159 participants (Actual) | Interventional | 2000-03-01 | Completed | ||
| [NCT02748772] | Phase 3 | 148 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00004635)
Timeframe: Date treatment consent signed to date off study, approximately 60 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Thalidomide | 117 |
| Placebo | 98 |
Time to progression is defined as follows: if the PSA returns to baseline (defined as the PSA value prior to starting leuprolide or goserelin) or increases to the absolute value of 5 ng/ml. (NCT00004635)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Thalidomide | 15 |
| Placebo | 9.6 |
17 reviews available for thalidomide and Cancer of Prostate
| Article | Year |
|---|---|
The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neopla | 2014 |
VEGF inhibitors and prostate cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
New therapeutic agents for castration-refractory prostate cancer.
Topics: Androstenes; Androstenols; Benzamides; Endothelins; Humans; Male; Nitriles; Orchiectomy; Phenylthioh | 2009 |
Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Male; Prostatic Neoplasms; Thalidomide; Treatm | 2009 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; | 2011 |
The role of IMiDs alone or in combination in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidom | 2012 |
Targeting angiogenesis as a promising modality for the treatment of prostate cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Progressi | 2012 |
Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; C | 2003 |
Current status of thalidomide and its role in the treatment of metastatic prostate cancer.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Male; Prostatic Neoplasms; Signa | 2003 |
Thalidomide: from teratogen to anti-angiogenic.
Topics: Angiogenesis Inhibitors; Humans; Male; Multiple Myeloma; Neoplasms; Prostatic Neoplasms; Thalidomide | 2001 |
Novel clinical trials in androgen-independent prostate cancer.
Topics: Androgens; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Cancer Vaccines; | 2002 |
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxyg | 2004 |
Thalidomide and analogues: current proposed mechanisms and therapeutic usage.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Administration Schedule; Humans; Male; Neova | 2004 |
Future therapies in hormone-refractory prostate cancer.
Topics: Antibodies, Monoclonal; Atrasentan; Boronic Acids; Bortezomib; Diphosphonates; DNA, Antisense; Forec | 2005 |
[Molecular-targeted therapy for prostate cancer].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Neoplasms, Hormone-De | 2008 |
[Thalidomide. Clinical trials in cancer].
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Multiple Myeloma; | 2000 |
Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies.
Topics: Adenoviridae; Angiogenesis Inhibitors; Apoptosis; Clinical Trials as Topic; Genes, p53; Genetic Ther | 2002 |
22 trials available for thalidomide and Cancer of Prostate
| Article | Year |
|---|---|
Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cohort Studies; Cytokines; Disease Progres | 2020 |
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Biopsy, N | 2008 |
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Angiogenesis Inhibitors; Antineoplastic Ag | 2009 |
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Topics: Adult; Aged; Carbohydrate Sulfotransferases; Docetaxel; Humans; Male; Middle Aged; Oligonucleotide A | 2010 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modal | 2010 |
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Mon | 2010 |
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progressi | 2010 |
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Surface; Antineoplastic Agents; Biomarkers, Tumor | 2012 |
Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Fre | 2012 |
An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Angiogenesis Inhibitors; Disease Progression; Endothelial Growth | 2003 |
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Topics: Administration, Oral; Humans; Lenalidomide; Male; Neoplasm Metastasis; Palliative Care; Prostatic Ne | 2004 |
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Topics: Aged; Androgens; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytog | 2006 |
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Rin | 2006 |
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Cadherins; Cell Communication; Combined Modality Therapy; Epithelial Ce | 2007 |
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.
Topics: Administration, Oral; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Cyclophospham | 2007 |
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
Topics: Aged; Androgens; Animals; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxyla | 2007 |
Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Granulocyte-Macrophage Colony-Stimulati | 2008 |
Pharmacokinetics of thalidomide in an elderly prostate cancer population.
Topics: Aged; Aged, 80 and over; Area Under Curve; Chromatography, High Pressure Liquid; Half-Life; Humans; | 1999 |
Thalidomide neuropathy in patients treated for metastatic prostate cancer.
Topics: Action Potentials; Age Factors; Aged; Aged, 80 and over; Brachial Plexus; Cohort Studies; Dose-Respo | 2001 |
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Endot | 2001 |
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Docetaxel; Humans; Male; Middl | 2001 |
36 other studies available for thalidomide and Cancer of Prostate
| Article | Year |
|---|---|
MODULATION OF ANTITUMOR IMMUNE RESPONSE IN MOUSE PROSTATE CANCER MODEL.
Topics: Animals; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Cell Proliferation; Dendritic Cells; Imm | 2017 |
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Topics: Apoptosis; Azepines; Benzodiazepines; Cell Cycle Proteins; Cell Proliferation; Cullin Proteins; Drug | 2017 |
Robotic assisted radical prostatectomy for localised prostate cancer in thalidomide generation.
Topics: Ectromelia; Female; Humans; Male; Maternal Exposure; Middle Aged; Prostate; Prostatectomy; Prostatic | 2018 |
Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cholesterol; Gene | 2018 |
Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line | 2015 |
Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Respo | 2017 |
Topics: Antibodies, Monoclonal; Cancer Vaccines; Cell Cycle Checkpoints; Humans; Immunomodulation; Immunothe | 2016 |
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Topics: Androgens; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassett | 2008 |
Prostate cancer: thalidomide for prostate cancer: is there progress?
Topics: Clinical Trials as Topic; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Male; Prostat | 2009 |
Reversal of docetaxel resistance with bevacizumab and thalidomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
[Study to castrate-resistant prostate cancer: AUO study AP 60/10].
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Docetaxel; Hum | 2011 |
Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dis | 2012 |
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosp | 2012 |
Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; | 2012 |
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Celecoxib; Dexamethasone | 2012 |
PSA response to thalidomide in patients with advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Drug Therapy, | 2002 |
Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions.
Topics: Animals; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Cell Transformation, Neoplastic; Clinical Tr | 2003 |
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associa | 2003 |
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Paclitax | 2003 |
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Topics: Adenocarcinoma; Androgens; Angiogenesis Inhibitors; Animals; Aorta; Cell Division; Drug Screening As | 2003 |
Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Biochemistry; Cell Division; Drug Screeni | 2004 |
Highlights from the XII European Cancer Conference Copenhagen, Denmark.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Humans | 2003 |
National Cancer Institute intramural approach to advanced prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomedical Research; Cancer Vaccines; Clinical Trials as Topi | 2002 |
Flutamide or thalidomide?
Topics: Communication; Flutamide; Humans; Male; Medication Errors; Prostatic Neoplasms; Thalidomide | 2004 |
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Humans; Immunoh | 2004 |
Inhibition of angiogenesis: thalidomide or low-molecular-weight heparin?
Topics: Angiogenesis Inhibitors; Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Male; Neovasculariza | 2005 |
Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Area Under Curve; Cyclophosphami | 2005 |
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Doc | 2006 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bort | 2006 |
Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cyclop | 2007 |
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetax | 2008 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Ant | 2008 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Ant | 2008 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Ant | 2008 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Ant | 2008 |
Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats.
Topics: Adenocarcinoma; Animals; Immunosuppressive Agents; Lung Neoplasms; Lymphatic Metastasis; Male; Neopl | 1996 |
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents.
Topics: Animals; Antineoplastic Agents; Enzyme-Linked Immunosorbent Assay; Genistein; Granulocyte-Macrophage | 1998 |
Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Phytogenic; Humans; Male; Mice; Mice, Nude; Pa | 1998 |